Education
About Us
Working with TipRanks
Follow Us
Omnicell (OMCL)
NASDAQ:OMCL
OMCL Stock Chart & Stats
$36.50
-$0.19(-0.44%)
At close: 4:00 PM EST
$36.50
-$0.19(-0.44%)
Day’s Range― - ―
52-Week Range$22.66 - $55.00
Previous CloseN/A
Volume97.52K
Average Volume (3M)589.34K
Market Cap
$1.66B
Enterprise Value$1.70B
Total Cash (Recent Filing)$196.52M
Total Debt (Recent Filing)$217.18M
Price to Earnings (P/E)844.9
Beta0.20
Next Earnings
May 13, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.40
Shares Outstanding44,876,522
10 Day Avg. Volume967,583
30 Day Avg. Volume589,339
Financial Highlights & Ratios
PEG Ratio-12.16
Price to Book (P/B)1.69
Price to Sales (P/S)1.76
P/FCF Ratio23.97
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue1.43
Enterprise Value/Gross Profit3.37
Enterprise Value/Ebitda18.58
Forecast
1Y Price Target
$58.20Price Target Upside59.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product AdoptionAnalyst notes a multi-year ramp for the Titan XT platform, supported by its integration with OmniSphere, creating a sustained replacement and upgrade opportunity as customers transition from legacy cabinets.
Recurring Revenue And MarginsAnalyst highlights a shift toward subscription software and tech-enabled services that should make revenue more predictable and support margin expansion through higher incremental product margins.
Valuation And Market Share OpportunityAnalyst points to a valuation discount versus historical levels and the potential to gain share during competitor renewal cycles, implying scope for multiple expansion if product adoption accelerates.
Bears Say
Bookings And Guidance MomentumAnalyst cautions that flat bookings guidance and weaker quarterly results reduce near-term momentum and temper upside to revenue growth expectations.
Cost And Tariff PressuresAnalyst warns that persistent tariffs, combined with ERP implementation costs and a less favorable product mix, are pressuring profit margins and weighing on earnings.
Customer Upgrade BehaviorAnalyst notes customer preference for top-swap upgrades over full fleet replacements may limit the total addressable market for large-scale conversions and slow the overall upgrade cycle.
Omnicell News
OMCL FAQ
What was Omnicell’s price range in the past 12 months?
Omnicell lowest stock price was $22.66 and its highest was $55.00 in the past 12 months.
What is Omnicell’s market cap?
Omnicell’s market cap is $1.66B.
When is Omnicell’s upcoming earnings report date?
Omnicell’s upcoming earnings report date is May 13, 2026 which is in 91 days.
How were Omnicell’s earnings last quarter?
Omnicell released its earnings results on Feb 05, 2026. The company reported $0.4 earnings per share for the quarter, missing the consensus estimate of $0.496 by -$0.096.
Is Omnicell overvalued?
According to Wall Street analysts Omnicell’s price is currently Undervalued.
Does Omnicell pay dividends?
Omnicell does not currently pay dividends.
What is Omnicell’s EPS estimate?
Omnicell’s EPS estimate is 0.33.
How many shares outstanding does Omnicell have?
Omnicell has 44,876,522 shares outstanding.
What happened to Omnicell’s price movement after its last earnings report?
Omnicell reported an EPS of $0.4 in its last earnings report, missing expectations of $0.496. Following the earnings report the stock price went down -16.299%.
Which hedge fund is a major shareholder of Omnicell?
Currently, no hedge funds are holding shares in OMCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omnicell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.20 (59.45% Upside)
$58.20 (59.45% Upside)
Blogger Sentiment
Bullish
OMCL Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 7.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.8%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bullish
Bullish news 82%
Bearish news 18%
Bearish news 18%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.11%
12-Months-Change
Fundamentals
Return on Equity
0.17%
Trailing 12-Months
Asset Growth
-6.89%
Trailing 12-Months
Company Description
Omnicell
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
OMCL Company Deck
OMCL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic outlook: Omnicell reported revenue and ARR growth, exceeded guidance midpoints for bookings and revenue, and launched strategic products (Titan XT, Omnisphere) with encouraging customer response and a stronger pipeline. However, the company faces margin pressure (tariffs and mix), lower GAAP/non-GAAP per-share results in the quarter and year, a meaningful cash balance reduction due to debt repayment and buybacks, and some service/retail segment headwinds. Management frames the adverse items as strategic investments (product launch, financing options, ERP transformation and go-to-market investments) that position the company for multi-year growth and higher recurring revenue, and 2026 guidance reflects modest top-line and EBITDA expansion while factoring in tariff and ERP costs. On balance, the positive operational momentum and guidance modestly outweigh the financial headwinds, but execution on margin recovery and conversion to Titan/Omnisphere will be critical.View all OMCL earnings summariesOMCL Stock 12 Month Forecast
Average Price Target
$58.20
▲(59.45% Upside)
Technical Analysis
Ownership Overview
2.99% Insiders
27.34% Mutual Funds
0.73% Other Institutional Investors
36.40% Public Companies and
Individual Investors